Dentsply Sirona, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US24906P1093
USD
11.27
0.16 (1.44%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.14 M

Shareholding (Mar 2025)

FII

18.21%

Held by 250 FIIs

DII

8.02%

Held by 101 DIIs

Promoter

0.03%

How big is Dentsply Sirona, Inc.?

22-Jun-2025

As of Jun 18, Dentsply Sirona, Inc. has a market capitalization of 3,768.62 million, with net sales of 3,719.00 million and a net profit of -908.00 million over the latest four quarters.

As of Jun 18, Dentsply Sirona, Inc. has a market capitalization of 3,768.62 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 3,719.00 million, while the sum of Net Profit for the same period is -908.00 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 1,942.00 million and Total Assets of 5,753.00 million.

Read More

What does Dentsply Sirona, Inc. do?

22-Jun-2025

Dentsply Sirona, Inc. is a mid-cap manufacturer of dental products and technologies, with recent net sales of $879 million and a net profit of $19 million. The company has a market cap of approximately $3.77 billion and key metrics include a P/E ratio of 22.00 and a dividend yield of 270.50%.

Overview:<BR>Dentsply Sirona, Inc. is a manufacturer of professional dental products and technologies operating in the Pharmaceuticals & Biotechnology industry within the mid-cap market segment.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 879 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 19 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,768.62 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 22.00 <BR>Dividend Yield: 270.50% <BR>Debt Equity: 0.96 <BR>Return on Equity: 8.84% <BR>Price to Book: 1.87<BR><BR>Contact Details:<BR>Address: 13320 Ballantyne Corporate Pl, CHARLOTTE NC: 28277-3607 <BR>Tel: ['1 717 8457511', '1 717 8497863'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.dentsplysirona.com/

Read More

Should I buy, sell or hold Dentsply Sirona, Inc.?

22-Jun-2025

Who are in the management team of Dentsply Sirona, Inc.?

22-Jun-2025

As of March 2022, the management team of Dentsply Sirona, Inc. includes Non-Executive Chairman Eric Brandt, CEO Donald Casey, and Directors Clyde Hosein, Michael Alfano, Willie Deese, and Betsy Holden, who oversee the company's strategic direction and operations.

As of March 2022, the management team of Dentsply Sirona, Inc. includes the following individuals:<BR><BR>- Mr. Eric Brandt, Non-Executive Independent Chairman of the Board<BR>- Mr. Donald Casey, Chief Executive Officer and Director<BR>- Mr. Clyde Hosein, Director<BR>- Dr. Michael Alfano, Independent Director<BR>- Mr. Willie Deese, Independent Director<BR>- Ms. Betsy Holden, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Dentsply Sirona, Inc. overvalued or undervalued?

20-Sep-2025

As of November 14, 2022, Dentsply Sirona, Inc. is considered overvalued with a valuation grade of risky, reflected by its P/E ratio of 22 and significant underperformance compared to the S&P 500, showing a year-to-date return of -29.29% and a 5-year return of -71.03%.

As of 14 November 2022, the valuation grade for Dentsply Sirona, Inc. moved from expensive to risky, indicating a shift in perception regarding its market value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 22, an EV to EBITDA of 9.86, and a Price to Book Value of 1.94. In comparison, peers such as The Cooper Cos., Inc. have a significantly higher P/E ratio of 34.28, while QIAGEN NV shows a fair valuation with a P/E of 24.20, suggesting that Dentsply Sirona's valuation does not align favorably with its industry counterparts.<BR><BR>The company's stock has underperformed relative to the S&P 500, with a year-to-date return of -29.29% compared to the index's 12.22%. This trend continues over longer periods, with a 5-year return of -71.03% against the S&P 500's 96.61%. Overall, these factors reinforce the conclusion that Dentsply Sirona, Inc. is currently overvalued.

Read More

Is Dentsply Sirona, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, Dentsply Sirona, Inc. is in a bearish trend with weak strength indicators, having underperformed the S&P 500 significantly with a year-to-date return of -29.29% compared to the S&P's 12.22%.

As of 5 August 2025, the technical trend for Dentsply Sirona, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the weekly MACD and Bollinger Bands both showing bearish signals, along with bearish moving averages. The Dow Theory also reflects a mildly bearish outlook on both weekly and monthly time frames. <BR><BR>In terms of performance, Dentsply Sirona has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -29.29% compared to the S&P 500's 12.22%, and a one-year return of -49.76% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROCE of 6.38%

  • The company has been able to generate a Return on Capital Employed (avg) of 6.38% signifying low profitability per unit of total capital (equity and debt)
  • OPERATING CASH FLOW(Y) Lowest at USD 283 MM
  • ROCE(HY) Lowest at -37.78%
  • DEBT-EQUITY RATIO (HY) Highest at 108.93 %
2

Risky -

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,487 Million (Small Cap)

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

196.12%

stock-summary
Debt Equity

1.04

stock-summary
Return on Equity

17.95%

stock-summary
Price to Book

1.78

Revenue and Profits:
Net Sales:
936 Million
(Quarterly Results - Jun 2025)
Net Profit:
-44 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.98%
0%
-18.98%
6 Months
-29.07%
0%
-29.07%
1 Year
-41.88%
0%
-41.88%
2 Years
-65.38%
0%
-65.38%
3 Years
-64.43%
0%
-64.43%
4 Years
-77.78%
0%
-77.78%
5 Years
-78.39%
0%
-78.39%

Dentsply Sirona, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
1.32%
EBIT Growth (5y)
4.55%
EBIT to Interest (avg)
5.20
Debt to EBITDA (avg)
2.74
Net Debt to Equity (avg)
0.96
Sales to Capital Employed (avg)
0.78
Tax Ratio
1.63%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
6.38%
ROE (avg)
7.23%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
1.94
EV to EBIT
23.29
EV to EBITDA
9.86
EV to Capital Employed
1.48
EV to Sales
1.57
PEG Ratio
NA
Dividend Yield
260.83%
ROCE (Latest)
6.36%
ROE (Latest)
8.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 106 Schemes (73.7%)

Foreign Institutions

Held by 250 Foreign Institutions (18.21%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 6.48% vs -2.87% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -331.58% vs 104.44% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "936.00",
          "val2": "879.00",
          "chgp": "6.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "199.00",
          "val2": "152.00",
          "chgp": "30.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "21.00",
          "val2": "17.00",
          "chgp": "23.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-231.00",
          "val2": "-4.00",
          "chgp": "-5,675.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.00",
          "val2": "19.00",
          "chgp": "-331.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "118.60%",
          "val2": "83.00%",
          "chgp": "3.56%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4.34% vs 1.10% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -589.39% vs 86.11% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,793.00",
          "val2": "3,965.00",
          "chgp": "-4.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "579.00",
          "val2": "638.00",
          "chgp": "-9.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "55.00",
          "val2": "64.00",
          "chgp": "-14.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,089.00",
          "val2": "-386.00",
          "chgp": "-182.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-910.00",
          "val2": "-132.00",
          "chgp": "-589.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "60.60%",
          "val2": "74.40%",
          "chgp": "-1.38%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
936.00
879.00
6.48%
Operating Profit (PBDIT) excl Other Income
199.00
152.00
30.92%
Interest
21.00
17.00
23.53%
Exceptional Items
-231.00
-4.00
-5,675.00%
Consolidate Net Profit
-44.00
19.00
-331.58%
Operating Profit Margin (Excl OI)
118.60%
83.00%
3.56%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 6.48% vs -2.87% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -331.58% vs 104.44% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
3,793.00
3,965.00
-4.34%
Operating Profit (PBDIT) excl Other Income
579.00
638.00
-9.25%
Interest
55.00
64.00
-14.06%
Exceptional Items
-1,089.00
-386.00
-182.12%
Consolidate Net Profit
-910.00
-132.00
-589.39%
Operating Profit Margin (Excl OI)
60.60%
74.40%
-1.38%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -4.34% vs 1.10% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -589.39% vs 86.11% in Dec 2023

stock-summaryCompany CV
About Dentsply Sirona, Inc. stock-summary
stock-summary
Dentsply Sirona, Inc.
Pharmaceuticals & Biotechnology
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures and markets solutions, including dental equipment and dental consumable products. The Company operates in two operating segments: Technologies & Equipment, and Consumables. The Technologies & Equipment segment is engaged in designing, manufacturing, sales and distribution of the Company's Dental Technology and Equipment Products and Healthcare Consumable Products. Its products include dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as consumable medical device products. The Consumables segment is engaged in designing, manufacturing, sales and distribution of the Company's Dental Consumable Products, which include preventive, restorative, endodontic and dental laboratory products. It also offers treatment planning and a clear aligner solution delivered directly to a consumer's home.
Company Coordinates stock-summary
Company Details
13320 Ballantyne Corporate Pl , CHARLOTTE NC : 28277-3607
stock-summary
Tel: 1 717 84575111 717 8497863
stock-summary
Registrar Details